Experience of Single Dose IV Iron (Ferric Derisomaltose) Use in a Rural District General Medicine Ambulatory Unit and Overview of Its Economic and Sustainability Impact
Author(s)
George Reid, MBChB1, Phil ODonnell, BSc Nursing2.
1Acute Internal Medicine, NHS Greater Glasgow and Clyde, GREENOCK, United Kingdom, 2Acute Internal Medicine, NHS GGC, Greenock, United Kingdom.
1Acute Internal Medicine, NHS Greater Glasgow and Clyde, GREENOCK, United Kingdom, 2Acute Internal Medicine, NHS GGC, Greenock, United Kingdom.
OBJECTIVES: To assess use of single dose IV iron as opposed to 2 visit dosing and its outcomes across a variety of domains (economic, environmental, efficacy and safety) Background - Historically IV iron has been given in a two dose regimen. Larger single doses are available for use however this is not incorporated in many local protocols. Single visits for patients would have number of savings, across a wealth of domains. Our ambulatory unit (NHS Hospital) serves patients from a wide geographical area, some require a ferry to attend the service. The unit takes medical referrals from primary and secondary care. Assessment and treatment with IV Iron is made on a clinical basis.
METHODS: Patients referred with severe symptomatic anaemia were assessed for iron deficiency. Low TSAT / Low Ferritin prompted need for IV iron. Data was collected on patient demographics, clinical suspicion around cause of anaemia, and follow up bloods at minimum 4 weeks.
RESULTS: 21 patients received single dose IV iron over 6 months. This represents 1.6% of unit workload. GI blood loss was most likely cause of Anaemia in 18/21 patient. 20/21 did not require a 2nd dose based on sustained improvement in haemoglobin at interval bloods. 0 patients had reaction to infusion. Cost savings for hospital (hospital time + equipment / medicine costs) approximately £180 per patient visit avoided. 30% of attending patients required a ferry, as a result of single dose 8 ferry journeys saved. Approximately 147 miles of travel avoided. 0 patients had reaction to infusion.
CONCLUSIONS: This study demonstrates safe effective use of single dose IV iron with a multitude of financial, environmental and personal savings in a small cohort of mainly Iron deficiency secondary to GI loss. Use of single dosing in other populations / services may yield similar benefits and savings.
METHODS: Patients referred with severe symptomatic anaemia were assessed for iron deficiency. Low TSAT / Low Ferritin prompted need for IV iron. Data was collected on patient demographics, clinical suspicion around cause of anaemia, and follow up bloods at minimum 4 weeks.
RESULTS: 21 patients received single dose IV iron over 6 months. This represents 1.6% of unit workload. GI blood loss was most likely cause of Anaemia in 18/21 patient. 20/21 did not require a 2nd dose based on sustained improvement in haemoglobin at interval bloods. 0 patients had reaction to infusion. Cost savings for hospital (hospital time + equipment / medicine costs) approximately £180 per patient visit avoided. 30% of attending patients required a ferry, as a result of single dose 8 ferry journeys saved. Approximately 147 miles of travel avoided. 0 patients had reaction to infusion.
CONCLUSIONS: This study demonstrates safe effective use of single dose IV iron with a multitude of financial, environmental and personal savings in a small cohort of mainly Iron deficiency secondary to GI loss. Use of single dosing in other populations / services may yield similar benefits and savings.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE454
Topic
Economic Evaluation
Disease
Gastrointestinal Disorders